NFATc1-IN-1 (C09-1156-878)

NFATc1-IN-1 (compound A04) is a potent inhibitor of RANKL-induced osteoclast formation, with an IC 50 of 1.57 μM. NFATc1-IN-1 shows anti-osteoclastogenic effects through reducing the RANKL-induced nuclear translocation of NFATc1. NFATc1-IN-1 can be used for osteoclastic diseases research.In VitroNFATc1-IN-1 (compound A04) (0-2.5 μM, 4 days) exhibits potent inhibitory activities on osteoclast formation and function, which eventually translates into decreased bone resorption. NFATc1-IN-1 (1.5-2.5 μM, 24 h) blocks NFATc1 nuclear translocation and decreases the level of NFATc1. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: Osteoclast precursor RAW 264.7 cells Concentration: 0, 0.5, 1.0, 1.5, 2.0 and 2.5 μM Incubation Time: 4 days Result: Markedly reduced the number and size of red TRAP-positive multinucleated osteoclasts at concentrations of 1.5, 2.0, and 2.5 μM. Significantly inhibited formation of osteoclasts in a dose-dependent manner (at 1.5, 2.0 and 2.5 μM), while showing no cytotoxic effects towards osteoclast precursor cells at concentrations of as high as 2.5 μM. ImmunofluorescenceCell Line: RAW264.7 cells Concentration: 1.5 or 2.5 μM Incubation Time: 24 h Result: Blocked NFATc1 nuclear translocation and decreased the level of NFATc1.Form:Solid. Specifications and Purity: 99%. Molecular Formula: C13H8F2INO2. Molecular Weight: 375.11.